The mechanisms by which pardaxin, a natural cationic antimicrobial peptide, targets the endoplasmic reticulum and induces c-FOS

Biomaterials

Volumn 35, Issue 11, 2014, Pages 3627-3640

  Ting, Chen Hung ^a   Huang, Han Ning ^b   Huang, Tsui Chin ^c   Wu, Chang Jer ^b   Chen, Jyh Yih ^a  

^a INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^b NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

C FOS; Calcium; Cationic antimicrobial peptide; Endoplasmic reticulum; Pardaxin

Indexed keywords

C-FOS; CALCIUM; CATIONIC ANTIMICROBIAL PEPTIDE; ENDOPLASMIC RETICULUM; PARDAXIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CALCIUM SIGNALING; CELL DEATH; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM; FEMALE; FISH VENOMS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS C-FOS; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894934931     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.032     Document Type: Article

References (58)

1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415:389-395.
2. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. JLeukoc Biol 2004, 75:39-48.
3. McPhee J.B., Hancock R.E. Function and therapeutic potential of host defence peptides. JPept Sci 2005, 11:677-687.
4. Dhople V., Krukemeyer A., Ramamoorthy A. The human beta-defensin-3, an antibacterial peptide with multiple biological functions. Biochim Biophys Acta 2006, 1758:1499-1512.
5. Durr U.H., Sudheendra U.S., Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006, 1758:1408-1425.
6. Powers J.P., Hancock R.E. The relationship between peptide structure and antibacterial activity. Peptides 2003, 24:1681-1691.
7. Papo N., Shahar M., Eisenbach L., Shai Y. Anovel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. JBiol Chem 2003, 278:21018-21023.
8. Huang T.C., Lee J.F., Chen J.Y. Pardaxin, an antimicrobial peptide, triggers caspase-dependent and ROS-mediated apoptosis in HT-1080 cells. Mar Drugs 2011, 9:1995-2009.
9. Hoskin D.W., Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 2008, 1778:357-375.
10. Gottler L.M., Ramamoorthy A. Structure, membrane orientation, mechanism, and function of pexiganan-a highly potent antimicrobial peptide designed from magainin. Biochim Biophys Acta 2009, 1788:1680-1686.
11. Ramamoorthy A. Beyond NMR spectra of antimicrobial peptides: dynamical images at atomic resolution and functional insights. Solid State Nucl Magn Reson 2009, 35:201-207.
12. Ramamoorthy A., Lee D.K., Narasimhaswamy T., Nanga R.P. Cholesterol reduces pardaxin's dynamics-a barrel-stave mechanism of membrane disruption investigated by solid-state NMR. Biochim Biophys Acta 2010, 1798:223-227.
13. Hallock K.J., Lee D.K., Omnaas J., Mosberg H.I., Ramamoorthy A. Membrane composition determines pardaxin's mechanism of lipid bilayer disruption. Biophys J 2002, 83:1004-1013.
14. Porcelli F., Buck B., Lee D.K., Hallock K.J., Ramamoorthy A., Veglia G. Structure and orientation of pardaxin determined by NMR experiments in model membranes. JBiol Chem 2004, 279:45815-45823.
15. Epand R.F., Ramamoorthy A., Epand R.M. Membrane lipid composition and the interaction of pardaxin: the role of cholesterol. Protein Pept Lett 2006, 13:1-5.
16. Thompson S.A., Tachibana K., Nakanishi K., Kubota I. Melittin-like peptides from the shark-repelling defense secretion of the sole Pardachirus pavoninus. Science 1986, 233:341-343.
17. Pal R., Barenholz Y., Wagner R.R. Pardaxin, a hydrophobic toxin of the Red Sea flatfish, disassembles the intact membrane of vesicular stomatitis virus. JBiol Chem 1981, 256:10209-10212.
18. Thennarasu S., Nagaraj R. Specific antimicrobial and hemolytic activities of 18-residue peptides derived from the amino terminal region of the toxin pardaxin. Protein Eng 1996, 9:1219-1224.
19. Huang H.N., Rajanbabu V., Pan C.Y., Chan Y.L., Wu C.J., Chen J.Y. Acancer vaccine based on the marine antimicrobial peptide pardaxin (GE33) for control of bladder-associated tumors. Biomaterials 2013, 34:10151-10159.
20. Huang T.C., Chen J.Y. Proteomic analysis reveals that pardaxin triggers apoptotic signaling pathways in human cervical carcinoma HeLa cells: cross talk among the UPR, c-Jun and ROS. Carcinogenesis 2013, 34:1833-1842.
21. Wu S.P., Huang T.C., Lin C.C., Hui C.F., Lin C.H., Chen J.Y. Pardaxin, a fish antimicrobial peptide, exhibits antitumor activity toward murine fibrosarcoma invitro and invivo. Mar Drugs 2012, 10:1852-1872.
22. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002, 4:E131-E136.
23. Eferl R., Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3:859-868.
24. Hess J., Angel P., Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. JCell Sci 2004, 117:5965-5973.
25. Grigoriadis A.E., Schellander K., Wang Z.Q., Wagner E.F. Osteoblasts are target cells for transformation in c-fos transgenic mice. JCell Biol 1993, 122:685-701.
26. Mahner S., Baasch C., Schwarz J., Hein S., Wolber L., Janicke F., et al. C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 2008, 99:1269-1275.
27. Bamberger A.M., Milde-Langosch K., Rossing E., Goemann C., Loning T. Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. JCancer Res Clin Oncol 2001, 127:545-550.
28. Liu H.C., Ting C.H., Wen H.L., Tsai L.K., Hsieh-Li H.M., Li H., et al. Sodium vanadate combined with L-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy. BMC Med 2013, 11:38.
29. Bhunia A., Domadia P.N., Torres J., Hallock K.J., Ramamoorthy A., Bhattacharjya S. NMR structure of pardaxin, a pore-forming antimicrobial peptide, in lipopolysaccharide micelles: mechanism of outer membrane permeabilization. JBiol Chem 2010, 285:3883-3895.
30. Bootman M.D., Collins T.J., Mackenzie L., Roderick H.L., Berridge M.J., Peppiatt C.M. 2-aminoethoxydiphenyl borate (2-APB) is a reliable blocker of store-operated Ca2+ entry but an inconsistent inhibitor of InsP3-induced Ca2+ release. FASEB J 2002, 16:1145-1150.
31. Seewald M.J., Olsen R.A., Sehgal I., Melder D.C., Modest E.J., Powis G. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues. Cancer Res 1990, 50:4458-4463.
32. Lallemand D., Spyrou G., Yaniv M., Pfarr C.M. Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts. Oncogene 1997, 14:819-830.
33. Yokoyama K., Hiyama A., Arai F., Nukaga T., Sakai D., Mochida J. C-Fos regulation by the MAPK and PKC pathways in intervertebral disc cells. PloS One 2013, 8:e73210.
34. Silvers A.L., Bachelor M.A., Bowden G.T. The role of JNK and p38 MAPK activities in UVA-induced signaling pathways leading to AP-1 activation and c-Fos expression. Neoplasia 2003, 5:319-329.
35. Wisdom R., Johnson R.S., Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999, 18:188-197.
36. Guller M., Toualbi-Abed K., Legrand A., Michel L., Mauviel A., Bernuau D., et al. c-Fos overexpression increases the proliferation of human hepatocytes by stabilizing nuclear cyclin D1. World J Gastroenterol 2008, 14:6339-6346.
37. Smeyne R.J., Vendrell M., Hayward M., Baker S.J., Miao G.G., Schilling K., et al. Continuous c-fos expression precedes programmed cell death invivo. Nature 1993, 363:166-169.
38. Ruther U., Garber C., Komitowski D., Muller R., Wagner E.F. Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 1987, 325:412-416.
39. Johnson R.S., Spiegelman B.M., Papaioannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 1992, 71:577-586.
40. Wang Z.Q., Ovitt C., Grigoriadis A.E., Mohle-Steinlein U., Ruther U., Wagner E.F. Bone and haematopoietic defects in mice lacking c-fos. Nature 1992, 360:741-745.
41. Dragunow M., Robertson H.A. Kindling stimulation induces c-fos protein(s) in granule cells of the rat dentate gyrus. Nature 1987, 329:441-442.
42. Morgan J.I., Cohen D.R., Hempstead J.L., Curran T. Mapping patterns of c-fos expression in the central nervous system after seizure. Science 1987, 237:192-197.
43. Sheng M., McFadden G., Greenberg M.E. Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB. Neuron 1990, 4:571-582.
44. Maki A., Berezesky I.K., Fargnoli J., Holbrook N.J., Trump B.F. Role of [Ca2+]i in induction of c-fos, c-jun, and c-myc mRNA in rat PTE after oxidative stress. FASEB J 1992, 6:919-924.
45. McConkey D.J., Nicotera P., Hartzell P., Bellomo G., Wyllie A.H., Orrenius S. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration. Arch Biochem Biophys 1989, 269:365-370.
46. Ferri K.F., Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 2001, 3:E255-E263.
47. Rizzuto R., Brini M., Murgia M., Pozzan T. Microdomains with high Ca2+ close to IP3-sensitive channels that are sensed by neighboring mitochondria. Science 1993, 262:744-747.
48. Korge P., Weiss J.N. Thapsigargin directly induces the mitochondrial permeability transition. Eur J Biochem 1999, 265:273-280.
49. Kidd J.F., Pilkington M.F., Schell M.J., Fogarty K.E., Skepper J.N., Taylor C.W., et al. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. JBiol Chem 2002, 277:6504-6510.
50. Park C.B., Kim H.S., Kim S.C. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 1998, 244:253-257.
51. Lau Y.E., Rozek A., Scott M.G., Goosney D.L., Davidson D.J., Hancock R.E. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect Immun 2005, 73:583-591.
52. Powers J.P., Tan A., Ramamoorthy A., Hancock R.E. Solution structure and interaction of the antimicrobial polyphemusins with lipid membranes. Biochemistry 2005, 44:15504-15513.
53. Casteels P., Ampe C., Jacobs F., Tempst P. Functional and chemical characterization of Hymenoptaecin, an antibacterial polypeptide that is infection-inducible in the honeybee (Apis mellifera). JBiol Chem 1993, 268:7044-7054.
54. Shai Y., Bach D., Yanovsky A. Channel formation properties of synthetic pardaxin and analogues. JBiol Chem 1990, 265:20202-20209.
55. Shai Y., Fox J., Caratsch C., Shih Y.L., Edwards C., Lazarovici P. Sequencing and synthesis of pardaxin, a polypeptide from the Red Sea moses sole with ionophore activity. FEBS Lett 1988, 242:161-166.
56. Vad B.S., Bertelsen K., Johansen C.H., Pedersen J.M., Skrydstrup T., Nielsen N.C., et al. Pardaxin permeabilizes vesicles more efficiently by pore formation than by disruption. Biophys J 2010, 98:576-585.
57. Zambrano F., Fleischer S., Fleischer B. Lipid composition of the golgi apparatus of rat kidney and liver in comparison with other subcellular organelles. Biochim Biophys Acta 1975, 380:357-369.
58. Westerhoff H.V., Hendler R.W., Zasloff M., Juretic D. Interactions between a new class of eukaryotic antimicrobial agents and isolated rat liver mitochondria. Biochim Biophys Acta 1989, 975:361-369.